OncoMatch/Clinical Trials/NCT04925648
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Is NCT04925648 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dasatinib and Darolutamide for metastatic prostate cancer.
Treatment: Dasatinib · Darolutamide — The study's purpose is to understand the appearance of your prostate-specific membrane antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib alone or in combination with anti-testosterone drug call darolutamide. Who is it for? You may be eligible to join this study if you have metastatic prostate cancer and had a recent PSMA scan showing low PSMA uptake Study Details: Participants will receive dasatinib 100 mg daily or dasatinib 100 mg daily and darolutamide 600 mg twice daily for 14 days. They will undergo another PSMA PET scan after 14 days. Participants will be followed up on day 7 of treatment and 30 days after treatment. It is hoped that this research will provide insight into the mechanism of PSMA expression in advanced prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: dasatinib (dasatinib)
Previous dasatinib for prostate cancer or other condition, eg CLL
Lab requirements
Blood counts
adequate hematologic function within 14 days before the first study treatment
Kidney function
adequate organ function within 14 days before the first study treatment
Liver function
adequate organ function within 14 days before the first study treatment
Adequate hematologic and organ function within 14 days before the first study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify